| __timestamp | Galapagos NV | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 1271353000 |
| Thursday, January 1, 2015 | 129714000 | 1620577000 |
| Friday, January 1, 2016 | 139574000 | 2052295000 |
| Sunday, January 1, 2017 | 218502000 | 2075142000 |
| Monday, January 1, 2018 | 322876000 | 2186100000 |
| Tuesday, January 1, 2019 | 427320000 | 3036600000 |
| Wednesday, January 1, 2020 | 523667000 | 2735000000 |
| Friday, January 1, 2021 | 491707000 | 2908100000 |
| Saturday, January 1, 2022 | 515083000 | 3592500000 |
| Sunday, January 1, 2023 | 241294000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Galapagos NV have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Regeneron consistently outpaced Galapagos, with its R&D expenses peaking at nearly 4.4 billion USD in 2023, a staggering 250% increase from 2014. In contrast, Galapagos saw a more modest growth, with its highest expenditure reaching approximately 524 million USD in 2020, before declining to 241 million USD in 2023. This divergence highlights Regeneron's aggressive pursuit of new therapies, while Galapagos adopts a more conservative approach. As the biotech landscape continues to shift, these spending patterns offer a glimpse into the strategic priorities of these industry leaders.
Novartis AG or Regeneron Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Sanofi and Regeneron Pharmaceuticals, Inc. Allocate Funds
Comparing Innovation Spending: Gilead Sciences, Inc. and Galapagos NV
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alpine Immune Sciences, Inc.
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Ionis Pharmaceuticals, Inc.
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for Regeneron Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Galapagos NV
TG Therapeutics, Inc. or Galapagos NV: Who Invests More in Innovation?
ACADIA Pharmaceuticals Inc. vs Galapagos NV: Strategic Focus on R&D Spending
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV
R&D Spending Showdown: Mesoblast Limited vs Galapagos NV